Hepatitis delta is a major determinant of liver decompensation events and death in HIV-infected patients

Clinical Infectious Diseases

Volumn 58, Issue 11, 2014, Pages 1549-1553

  Fernández Montero, José Vicente ^a   Vispo, Eugenia ^a   Barreiro, Pablo ^a   Sierra Enguita, Rocío ^a   De Mendoza, Carmen ^a,b   Labarga, Pablo ^a   Soriano, Vincent ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

Cirrhosis; Death; Hepatitis (HBV, HCV, and HDV); HIV

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIVIRUS AGENT; HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY; ANTIRETROVIRUS AGENT;

ADULT; ANTIVIRAL THERAPY; ARTICLE; ASCITES; BLEEDING; BRAIN DISEASE; DECOMPENSATED LIVER CIRRHOSIS; DELTA AGENT HEPATITIS; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MORBIDITY; MORTALITY; PRIORITY JOURNAL; SPAIN; TREATMENT RESPONSE; VIRAL CLEARANCE; COINFECTION; COMPLICATION; EPIDEMIOLOGY; HEPATITIS D; HIV INFECTIONS; LIVER FAILURE; MIDDLE AGED; RETROSPECTIVE STUDY; SURVIVAL;

ADULT; ANTI-RETROVIRAL AGENTS; COINFECTION; FEMALE; HEPATITIS B; HEPATITIS C; HEPATITIS D; HIV INFECTIONS; HUMANS; LIVER FAILURE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SPAIN; SURVIVAL ANALYSIS;

EID: 84900450817     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu167     Document Type: Article

References (32)

1. Rizzetto M, Canese M, Arico S, et al. Immunofluorescence detection of new antigen-antibody system (delta/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers. Gut 1977; 18:997-1003.
2. Flores R, Ruiz-Ruiz S, Serra P. Viroids and hepatitis delta virus. Sem Liver Dis 2012; 32:201-10.
3. Wedemeyer H, Manns M. Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead. Nat Rev Gastroenterol Hepatol 2010; 7:31-40.
4. Farci P, Niro G. Clinical features of hepatitis D. Sem Liver Dis 2012; 32:228-36.
5. Puoti M, Moioli M, Travi G, et al. The burden of liver disease in HIVinfected patients. Semin Liver Dis 2012; 32:103-13.
6. Weber R, Ruppik M, Rickenbach M, et al. Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study. HIV Med 2013; 14:195-207.
7. Soriano V, Poveda E, Vispo E, Barreiro P. Hepatitis B in HIV-infected patients. Clin Liver Dis 2013; 17:489-501.
8. Soriano V, Vispo E, Fernández-Montero JV, et al. Update on HIV/HCV coinfection. Curr HIV/AIDS Rep 2013; 10:226-34.
9. Rizzetto M. Hepatitis D: thirty years after. J Hepatol 2009; 50:1043-50.
10. Gunsar F. Treatment of delta hepatitis. Expert Rev Anti Infect Ther 2013; 11:489-98.
11. Soriano V, Grint D, D?Arminio-Monforte A, et al. Hepatitis delta in HIV-infected individuals in Europe. AIDS 2011; 25:1987-92.
12. Fernández-Montero JV, Barreiro P, Vispo E, et al. Liver stiffness predicts liver-related complications and mortality in HIV patients with chronic hepatitis C on antiretroviral therapy. AIDS 2013; 27:1129-34.
13. Fernandez-Montero JV, Barreiro P, Vispo E, et al. Liver fibrosis progression in HIV-HCV-coinfected patients treated with distinct antiretroviral drugs and impact of peginterferon-ribavirin therapy [Epub ahead of print]. Antiviral Ther 2013. doi:10.3851/IMP2703.
14. Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 2008; 48:835-47.
15. Thompson M, Aberg J, Hoy J, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012; 308:387-402.
16. European AIDS Clinical Society Guidelines (EACS). Version 7.0. October 2013. Available at: http://www.europeanaidsclinicalsociety.org. Accessed 1 December 2013.
17. Department of Health and Human Services. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available at: http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf. Accessed 1 December 2013.
18. Kucirka L, Farzadegan H, Feld J, et al. Prevalence, correlates, and viral dynamics of hepatitis delta among injecting drug users. J Infect Dis 2010; 202:845-52.
19. Gish R, Yi D, Kane S, et al. Coinfection with hepatitis B and D: epidemiology, prevalence and disease in patients in northern California. J Gastroenterol Hepatol 2013; 28:1521-5.
20. Castellares C, Barreiro P, Mart?n-Carbonero L, et al. Liver cirrhosis in HIV-infected patients: prevalence, etiology and clinical outcome. J Viral Hepat 2008; 15:165-72.
21. Lee C, Tsai H, Lee S, et al. Higher rate of hepatitis events in patients with human immunodeficiency virus, hepatitis B, and hepatitis D genotype II infection: A cohort study in a medical center in southern Taiwan [Epub ahead of print]. J Microbiol Immunol Infect 2013. doi:10.1016/j.jmii.2013.08.001.
22. Sheng W, Hung C, Kao J, et al. Impact of hepatitis D virus infection on the long-term outcomes of patients with hepatitis B virus and HIV coinfection in the era of highly active antiretroviral therapy: a matched cohort study. Clin Infect Dis 2007; 44:988-95.
23. Mart?n-Carbonero L, Teixeira T, Poveda E, et al. Clinical and virological outcomes in HIV-infected patients with chronic hepatitis B on longterm nucleos(t)ide analogues. AIDS 2011; 25:73-9.
24. Mira J, Rivero-Juárez A, López-Cortés L, et al. Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis. Clin Infect Dis 2013; 56:1646-53.
25. Yurdaydin C. Treatment of chronic delta hepatitis. Sem Liver Dis 2012; 32:237-44.
26. Noureddin M, Gish R. Hepatitis delta: epidemiology, diagnosis and management 36 years after discovery. Curr Gastroenterol Rep 2014; 16:365-72.
27. Lamers M, Kirgiz Ö, Heidrich B,Wedemeyer H, Drenth J. Interferon-α for patients with chronic hepatitis delta: a systematic review of randomized clinical trials. Antivir Ther 2012; 17:1029-37.
28. Heidrich B, Manns M, Wedemeyer H. Treatment options for hepatitis delta virus infection. Curr Infect Dis Reports 2013; 15:31-8.
29. Niro G, Ciancio A, Tillman H, et al. Lamivudine therapy in chronic delta hepatitis: a multicentre randomized-controlled pilot study. Aliment Pharmacol Ther 2005; 22:227-32.
30. Wedemeyer H, Yurdayd?n C, Dalekos G, et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med 2011; 364:322-31.
31. Sheldon J, Ramos B, Toro C, et al. Does treatment of hepatitis B virus (HBV) infection reduce hepatitis delta virus (HDV) replication in HIVHBV-HDV-coinfected patients? Antivir Ther 2008; 13:97-102.
32. Vispo E, Sierra-Enguita R, Barreiro P, et al. Efficacy of prolonged tenofovir therapy on hepatitis delta in HIV-infected patients. J Infect Dis 2014. In press.